Active Ingredient History
Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. The most potent are members of genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from about a dozen other genera. Psilocybin is itself biologically inactive but is quickly converted by the body to psilocin, which has mind-altering effects similar, in some aspects, to those of lysergic acid diethylamide (LSD), mescaline, and dimethyltryptamine (DMT). In general, the effects include euphoria, visual and mental hallucinations, changes in perception, distorted sense of time, and perceived spiritual experiences. It can also cause adverse reactions such as nausea and panic attacks. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Alcohol-Induced Disorders (Phase 2)
Alcoholism (Phase 2)
Alzheimer Disease (Early Phase 1)
Amnesia (Phase 1)
Amphetamine-Related Disorders (Phase 1/Phase 2)
Anhedonia (Phase 2)
Anorexia Nervosa (Phase 2)
Anxiety (Phase 2)
Back Pain (Phase 1/Phase 2)
Behavior (Phase 2)
Biliary Tract Neoplasms (Phase 1)
Binge-Eating Disorder (Phase 2)
Bipolar Disorder (Phase 2)
Body Dysmorphic Disorders (Phase 2)
Borderline Personality Disorder (Phase 2)
Burnout, Professional (Phase 1/Phase 2)
Burnout, Psychological (Phase 1/Phase 2)
Caregiver Burden (Phase 1/Phase 2)
Central Nervous System Agents (Phase 1)
Chemically-Induced Disorders (Phase 1)
Chronic Pain (Phase 2)
Cluster Headache (Phase 1/Phase 2)
Cocaine-Related Disorders (Phase 2)
Cognition Disorders (Phase 2)
Cognitive Dysfunction (Phase 2)
COVID-19 (Phase 1/Phase 2)
Death (Early Phase 1)
Demoralization (Phase 2)
Depression (Phase 2)
Depressive Disorder (Phase 2)
Depressive Disorder, Major (Phase 2)
Depressive Disorder, Treatment-Resistant (Phase 3)
Diagnostic Self Evaluation (Early Phase 1)
Drug-Related Side Effects and Adverse Reactions (Early Phase 1)
Fibromyalgia (Phase 2)
Fragile X Syndrome (Phase 2)
Grief (Phase 1)
Hallucinogens (Phase 1)
Headache (Phase 1)
Healthy Volunteers (Phase 1/Phase 2)
Heart (Phase 1)
Hospices (Phase 2)
Lymphoma (Phase 1)
Melanoma (Phase 2)
Mental Disorders (Phase 2)
Methamphetamine (Phase 1)
Migraine Disorders (Phase 2)
Mood Disorders (Early Phase 1)
Neoplasms (Phase 2/Phase 3)
Neuroimaging (Phase 1)
Obsessive Behavior (Phase 2)
Obsessive-Compulsive Disorder (Phase 1/Phase 2)
Opioid-Related Disorders (Phase 2)
Pain (Phase 2)
Pain Management (Phase 2)
Pancreatic Neoplasms (Phase 1)
Parkinson Disease (Phase 2)
Perception (Phase 1)
Phantom Limb (Phase 1)
Pharmacokinetics (Phase 1)
Pharmacologic Actions (Phase 1)
Post-Lyme Disease Syndrome (Phase 1)
Post-Traumatic Headache (Phase 1)
Psilocybin (Phase 2)
Psychological Distress (Phase 1/Phase 2)
Psychotherapy (Phase 2)
Psychotropic Drugs (Phase 1)
Religion (Phase 1)
Sleep (Phase 1)
Sleep Disorders, Intrinsic (Early Phase 1)
Stress Disorders, Post-Traumatic (Phase 2)
Stress Disorders, Traumatic (Phase 2)
Substance-Related Disorders (Phase 1)
Suicidal Ideation (Phase 2)
Terminally Ill (Phase 2)
Therapeutic Uses (Phase 1)
Tobacco Use Disorder (Phase 2)
Toxicity Tests (Early Phase 1)
Trauma and Stressor Related Disorders (Phase 2)
Vagus Nerve Stimulation (Phase 1)
Visual Pathways (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue